CAL-101 (Idelalisib) is a potent, selective PI3Kδ inhibitor. It affects the PI3K/AKT/mTOR signaling pathway by binding to the kinase ATP-binding cleft and reducing AKT phosphorylation, effectively inhibiting tumor cell proliferation and promoting apoptosis in hematological malignancies.
CAL-101 (Idelalisib) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for CAL-101 (Idelalisib) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.